BBA
AEGR

Baker Bros. Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History

Baker Bros. Advisors’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-14,300
Closed -$374K – 134
2015
Q1 		$374K Buy
+14,300
New +$364K ﹤0.01% 125
2014
Q3 		– Sell
-413,922
Closed -$13.3M – 111
2014
Q2 		$13.3M Sell
413,922
-100,000
-19% -$3.72M 0.16% 41
2014
Q1 		$23.7M Buy
513,922
+13,922
+3% +$816K 0.3% 36
2013
Q4 		$35.5M Sell
500,000
-320,275
-39% -$24.5M 0.5% 27
2013
Q3 		$70.3M Sell
820,275
-104,068
-11% -$8.82M 1% 16
2013
Q2 		$58.5M Buy
+924,343
New +$49.1M 1.16% 14

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Baker Bros. Advisors's AEGR Position: Q2 2015 in Review

Baker Bros. Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2015, closing a stake of 14,300 shares — an estimated $374K sold.

Baker Bros. Advisors first reported a position in AEGR in Q2 2013 and held it in 6 quarters. The position peaked at $70.3M in Q3 2013. 97 funds tracked by Wall St. Rank hold AEGR as of Q2 2015.

  • Baker Bros. Advisors reported no remaining Aegerion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Baker Bros. Advisors sold 14,300 Aegerion Pharmaceuticals shares in Q2 2015, an estimated $374K.
  • Baker Bros. Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 6 quarters.
  • Baker Bros. Advisors's Aegerion Pharmaceuticals position peaked at $70.3M in Q3 2013.
  • 97 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2015.

Based on Baker Bros. Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.